Cylapril weight-loss claim halted
This article was originally published in The Tan Sheet
Executive SummaryThe Electronic Retailing Self-Regulation Program recommends Adrenal Fatigue Institute discontinue claims that its supplement Cylapril helps consumers "lose the weight in just two easy steps," according to a June 24 report. The marketer failed to substantiate weight-loss claims during a routine review by ERSP. The firm agreed to discontinue the claims and claims that Cylapril is the "only product of its kind." The marketer supported claims that the supplement improves adrenal functioning, metabolism and fatigue, added ERSP
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.